001     307665
005     20260116151530.0
024 7 _ |a 10.1016/j.cell.2025.12.046
|2 doi
024 7 _ |a pmid:41534530
|2 pmid
024 7 _ |a 0092-8674
|2 ISSN
024 7 _ |a 1097-4172
|2 ISSN
037 _ _ |a DKFZ-2026-00122
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wang, Jian
|b 0
245 _ _ |a EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.
260 _ _ |a [Cambridge, Mass.]
|c 2026
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768572712_1240525
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Epstein-Barr virus (EBV) is involved in causing and probably also in perpetuating multiple sclerosis (MS). Among several mechanisms of how EBV may contribute are transcriptome alterations, including changes of antigen processing and preferential presentation of both viral and self-antigens. Here, we report that EBV reprograms the transcriptome and immunopeptidome presented on the MS-associated human leukocyte antigen (HLA)-DR15 molecules of infected B cells. Identical myelin basic protein (MBP) peptides were found to be presented on both EBV-infected B cells and MS brain tissue but not primary B cells and thymic tissue. Peripheral memory and cerebrospinal fluid (CSF)-derived CD4+ T cells of HLA-DR15+ MS patients responded to MBP peptides, MBP(78-90) and/or MBP(83-90), and T cell clones raised with these peptides recognized all MBP peptides ending at amino acid MBP90 in MS brain tissue. Our study provides a new mechanistic link for how the environmental and genetic risk factors, EBV infection and HLA-DR15 haplotype, may contribute jointly to MS.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a B cells
|2 Other
650 _ 7 |a Epstein-Barr virus
|2 Other
650 _ 7 |a autoreactive CD4(+) T cells
|2 Other
650 _ 7 |a brain tissue
|2 Other
650 _ 7 |a immunopeptidome
|2 Other
650 _ 7 |a multiple sclerosis
|2 Other
650 _ 7 |a myelin basic protein peptide
|2 Other
650 _ 7 |a thymic tissue
|2 Other
700 1 _ |a Qiu, Yuhan
|b 1
700 1 _ |a Marti, Zoe
|b 2
700 1 _ |a Li, Fengqi
|b 3
700 1 _ |a Wacker, Marcel
|b 4
700 1 _ |a Oldrati, Pietro
|b 5
700 1 _ |a Mühlenbruch, Lena
|0 P:(DE-He78)c6de4d8f2028af485dd5838bebdcb3e1
|b 6
700 1 _ |a Jin, Linlin
|b 7
700 1 _ |a Zhang, Hongxia
|b 8
700 1 _ |a Xu, Wen
|b 9
700 1 _ |a Li, Tingting
|b 10
700 1 _ |a Roschitzki, Bernd
|b 11
700 1 _ |a Faigle, Wolfgang
|b 12
700 1 _ |a Liu, Yingjun
|b 13
700 1 _ |a Nguyen, Julie T
|b 14
700 1 _ |a Lee, Jar-How
|b 15
700 1 _ |a Haunerdinger, Veronika
|b 16
700 1 _ |a Hauri-Hohl, Mathias
|b 17
700 1 _ |a Momburg, Frank
|b 18
700 1 _ |a Bauer, Jens
|0 P:(DE-He78)f01eee7fbf54dc1fe47b67c4eff9fdec
|b 19
|u dkfz
700 1 _ |a Rammensee, Hans-Georg
|0 P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc
|b 20
700 1 _ |a Sospedra, Mireia
|b 21
700 1 _ |a Magliozzi, Roberta
|b 22
700 1 _ |a Reynolds, Richard
|b 23
700 1 _ |a Walz, Juliane
|0 P:(DE-He78)aa8b428f7b1df6694113a5a7d3c4832a
|b 24
|u dkfz
700 1 _ |a Martin, Roland
|b 25
773 _ _ |a 10.1016/j.cell.2025.12.046
|g p. S0092867425014953
|0 PERI:(DE-600)2001951-8
|p nn
|t Cell
|v nn
|y 2026
|x 0092-8674
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)c6de4d8f2028af485dd5838bebdcb3e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)f01eee7fbf54dc1fe47b67c4eff9fdec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)aa8b428f7b1df6694113a5a7d3c4832a
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-01
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a IF >= 60
|0 StatID:(DE-HGF)9960
|2 StatID
|b CELL : 2022
|d 2025-01-01
920 1 _ |0 I:(DE-He78)TU01-20160331
|k TU01
|l DKTK Koordinierungsstelle Tübingen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)TU01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21